Browsing Tag
NYSE
113 posts
H.B. Fuller (NYSE: FUL) receives $1.2bn Ancora bid for Building Adhesives unit
Ancora's $1.2 billion cash bid for H.B. Fuller's Building Adhesives unit forces a governance test after the board's AMS acquisition pushed leverage to 4x.
Embraer S.A. (NYSE: EMBJ) delivers strongest second quarter in company history
Embraer's Q2 revenue hit $2.2 billion with a 38% adjusted net income surge, and shares neared a 52-week high as 2026 EBIT and cash targets were raised.
Teledyne Technologies to acquire Varex Imaging, adding photon counting X-ray detectors to its imaging portfolio
Teledyne is paying a 52% premium for Varex Imaging, taking the only independent commercial photon counting CT detector supplier as OEMs race to catch Siemens.
Inside the Virginia intervention: What Abigail Spanberger actually wants from NextEra and Dominion
Spanberger's intervention does not remove SCC approval authority, but it raises the political cost of a clean pass on the NextEra-Dominion $67 billion deal.
Sun Life Financial Q2 profit jumps 41% to C$1bn on Canada, Asia and U.S. strength
Sun Life's Q2 underlying income rose 11% to C$1.12B and ROE hit 19.1%, but leverage climbed to 23.8% and MFS net outflows widened to US$22.9 billion.
ESS Tech signs 500 MWh sodium-ion framework LOI with Juniper Energy
ESS Tech's 500 MWh Juniper Energy LOI targets a 2027 California start, with Q2 results due 13 August and cash below $14M testing the sodium-ion pivot at NYSE.
Motorola Solutions (NYSE: MSI) raises 2026 outlook on record public safety backlog, but Q3 guide slips below Wall Street
Motorola Solutions raised 2026 revenue guide to $12.98 billion on a record $15.6 billion backlog and public safety demand, with Q3 outlook a shade softer.
Why Visa is paying Permira nearly double for BioCatch after only two years
Visa's $2.4 billion BioCatch acquisition targets fiscal Q2 2027 close, testing whether behavioural biometrics can outrun the AI-driven banking fraud surge.
BP posts $5.7bn Q2 underlying profit as new CEO Meg O’Neill orders a reset
BP Q2 underlying RC profit hits $5.7bn and the dividend rises 4%. New CEO Meg O'Neill admits BP wrote off too much value, orders a portfolio and cost reset.
Why CONMED’s (NYSE: CNMD) reported sale review could reset the medtech value debate after Q2
CONMED’s sale speculation, Q2 results and AirSeal update put CNMD back in focus. Read how medtech M&A interest could reshape its turnaround story.